Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine. Neutralizing antibody responses 1 month after ...

A new therapeutic method using human antibodies to neutralize toxins was found to prevent Clostridium difficile-induced death in hamsters say researchers from New Jersey and Massachusetts. C.

Findings presented at the American Society for Microbiology's ASM Microbe conference show that the ultra-sensitive Clostridium difficile toxin A/B assay in development for use on the Sgx Clarity™ ...

Clostridiodes difficile infection has become a leading cause of severe, sometimes fatal diarrheal illness. It flourishes best in hospitals and long-term care facilities where people are on long-term ...

C. diff is a common bacterial infection of the gut, and it can be deadly. In two Phase 3 clinical trials, an infusion of Bezlotoxumab cut the risk for a recurrent infection by 10-percent over 12 weeks ...

Singulex’s Clarity C. diff toxin A/B assay, a rapid C. diff toxin test, has made its commercial debut, the company announced. “The Clarity toxin A/B assay offers a new approach to testing for C. diff ...

In a hamster model of Clostridium difficile, infection with C. difficile strains producing either toxin A or toxin B caused fulminant disease, according to a research team from the University of ...

Isolating asymptomatic C. diff carriers linked with lower incidence of infection Screening and isolating asymptomatic Clostridium difficile carriers was associated with a reduction in incidence of ...

Clostridium difficile infection is the leading cause of gastroenteritis-associated death and has become the most common cause of health care–associated infections in US hospitals. For long-term care ...